文献类型：期刊文献

英文题名：Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis

作者：Ma, Long[1,2];Jin, Gang[2];Yao, Keying[3];Yang, Yi[2];Chang, Ruitong[2];Wang, Wenhao[2];Liu, Jiawei[2];Zhu, Zijiang[2]

第一作者：Ma, Long;马利

通信作者：Zhu, ZJ[1]

机构：[1]Gansu Univ Chinese Med, Gansu Prov Hosp, Clin Med Coll 1, Lanzhou, Peoples R China;[2]Gansu Prov Hosp, Dept Thorac Surg, Lanzhou, Peoples R China;[3]Lanzhou Univ, Clin Med Coll 2, Lanzhou, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Thorac Surg, Lanzhou, Peoples R China.

年份：2021

卷号：12

外文期刊名：FRONTIERS IN PHARMACOLOGY

收录：;Scopus(收录号：2-s2.0-85113734192);WOS:【SCI-EXPANDED(收录号:WOS:000693881800001)】；

基金：Funding This work was supported by a grants from the National Natural Science Foundation of China (Nos. 31760259).

语种：英文

外文关键词：anti-PD-1; PD-L1 inhibitors; DOCETAXEL; systematic review; meta-analysis; NSCLC

摘要：Objective: To evaluate the efficacy and safety of anti-PD-1/PD-L1 Inhibitors versus docetaxel for non-small cell lung cancer by meta-analysis. Methods: Randomized controlled trials (RCTs) about anti-PD-1/PD-L1 Inhibitors versus docetaxel on the treatment of NSCLC were searched in CNKI, WF, VIP, PubMed, EMBASE, Cochrane Library, and Web of Science databases. Two reviewers independently screened literature, extracted data and evaluated the risk of bias of eligible studies. Meta-analysis was performed by RevMan5.3 software. Results: Compared with the use of docetaxel chemotherapy for NSCLC, the overall survival and progression-free survival of the anti-PD-1/PD-L1 Inhibitors regimen are better [overall survival: (HR= 0.73, 95%CI:0.69 similar to 0.77, P<0.00001], progression-free survival: (HR= 0.89, 95%CI:0.83 similar to 0.94, P<0.00001]), and lower incidence of treatment-related grade 3 or higher adverse events ([OR=0.20, 95% CI: 0.13 similar to 0.31, P<0.00001]). Conclusion: Compared with the docetaxel chemotherapy regimen, the anti-PD-1/PD-L1 Inhibitors has certain advantages in terms of efficacy and safety. The results still need to be confirmed by a multi-center, large sample, and high-quality research.